ImmunoLin® is a protein-based (>90%) dietary supplement containing over 50% immunoglobulins that helps support digestive function and a healthy mucosal immune system.

The protein mixture found inImmunoLin® is serum-derived bovine immunoglobulin/protein isolate (SBI) and is manufactured using a tightly-controlled and highly reproducible process at an FDA-inspected facility. Research studies provide evidence that the diversity of immunoglobulins and proteins found in ImmunoLin® are safe and help improve digestive health and nutritional status by decreasing immune activation through mechanisms that involve antigen binding and strengthening gut barrier function. Have more questions? Click the link to see what others most freque...

Read more

Entera Health and Ortho Molecular Products announce a multi-year partnership to develop a non-dairy immune health dietary supplement available exclusively through Ortho Molecular Product’s direct-to-practitioner network.

Ankeny, Iowa, United States - January 16, 2018 /MarketersMedia/ — Entera Health, Inc. of Ankeny, IA, has announced a strategic partnership with Ortho Molecular Products, Inc. of Stevens Point, WI. In this partnership, Ortho Molecular Products retains exclusive rights to develop and promote a dietary supplement containing Entera Health’s flagship ingredient, ImmunoLin®, a serum-derived bovine immunoglobulin concentrate. Launching in February 2018, SBI Protect will be the only dietary supplement of its...

Read more

Paper published in Gastroenterology & Hepatology discusses a number of non-pharmaceutical treatment options in GI care

Over the past few years, medical foods have emerged as a tool for physicians to manage many gastrointestinal disorders, such as IBS, IBD, and HIV-associated enteropathy, as well as nongastrointestinal disorders. This paper discusses how multiple animal and human studies have provided the data purporting to show the efficacy of medical foods.

Safe medical foods may be the initial step in managing various gastrointestinal disorders before moving to drugs with known and higher side-effect profiles. In addition, because the medical foods reviewed in this article do not have major food or drug interactions, they may be consid...

Read more

Entera Health Inc. is excited about recognition for its premier brand.

Last year was a notable year for irritable bowel syndrome in the mainstream media. Even more notable was that two of those articles included a medical food product indicated for the dietary management of chronic diarrhea and loose stools – EnteraGam® (serum-derived bovine immunoglobulin/protein isolate, SBI).

Prevention Magazine’s November issue included the article: Problem Solved! Irritable Bowel Syndrome, which included information about EnteraGam®:

Inflammation from an injury, an infection, or a chronic condition may make the gut’s structure more permeable, providing easier access for toxins. EnteraGam® is prescribed “medical food” consisting mainly of beef protein that helps facilitate gut healing and promote intestinal immunity…. Pilot studies find that mixing 5 to 10 g of the powder into liquids or soft foods each day can thicken stools and relieve symptoms like abdominal pain and bloating.

Earlier in the year, American Gastroenterological Association's (AGA) “IBS in America” national survey reported:

.. only “prescription meds, EnteraGam®” and “prescription meds approved for IBS-D” garnered “very satisfied” ratings by more than one-quarter of IBS-D patients.

Read the full Prevention article or IBS in America.

“We’re e...

Read more

The Company has redefined foundational information for its medical food product EnteraGam® (serum-derived bovine immunoglobulin/protein isolate, SBI)

Entera Health, Inc. today announced that it has revised its statement of intended use for EnteraGam® to now read, “EnteraGam® is a medical food product intended for the dietary management of chronic diarrhea and loose stools. EnteraGam® must be administered under medical supervision.”

The company has timed the revision to coincide with the 2016 American College of Gastroenterology’s (ACG) Annual Scientific Meeting & Postgraduate Course, where Entera Health will have a booth at the Venetian in Las Vegas, NV, from Friday, October 14 to Wednesday, October 19.


Read more

Clinical and nonclinical data to be presented for EnteraGam® (Serum-derived bovine immunoglobulin/protein isolate, SBI) at DDW 2016.

Entera Health, Inc. today announces four poster presentations that will take place at the Digestive Disease Week 2016 Annual Meeting in San Diego, CA, from Saturday, May 21 – Tuesday, May 24, 2016.

Monday, May 23 – Poster Session. 9:30am – 4:00pm (Authors present Noon – 2:00pm)
Poster Mo1667: The Effects of Dietary Protein and Serum-Derived Bovine Immunoglobulin/Protein Isolate in a Murine Model of Clostridium difficile Infection.
Christopher J. Detzel, PhD, Entera Health, Ankeny, IA.

Tuesday, May 24 – Poster Session. 9:30am – 4:00pm (Authors present Noon – 2:00pm...

Read more

Entera Health releases its new MOA animation video for prescription medical food product EnteraGam® (serum-derived bovine immunoglobulin/protein isolate, SBI) used in managing IBS-D and IBD.

Entera Health Inc. debuted it's new "Tight Junctions and the Intestinal Gut Barrier" MOA animation video to widespread audience appreciation and accolades at the 2015 American College of Gastroenterology (ACG) National Conference a few months ago. The company continues to receive positive feedback from the many healthcare practitioners lauding the ways they have found the video very helpful.

This informative and exciting animation video dives deep into the cellular mode of barrier function; however, the main take-away is the core binding feature ...

Read more

Study Results Presented at the Conference on Retroviruses and Opportunistic Infections (CROI) Demonstrate Benefits of Serum-Derived Bovine Immunoglobulin/Protein Isolate (SBI), the Main Ingredient in EnteraGam®, in HIV Patients with HIV-Associated Immune Dysfunction.

Entera Health, Inc. today announced additional results from a multi-center study evaluating the impact of SBI in patients with HIV-associated enteropathy and on long-term suppressive antiretroviral therapy (ART). Previous analysis showed that SBI led to increases in peripheral CD4+ T-cells after 4 and 24 weeks (p≤0.02) among patients in the lowest quartile for baseline (BL) CD4+ T-cells (≤418 cells/µL) (1). Results reported on the follow up analysis showed ...

Read more

Results from the “IBS in America” national survey conducted by the American Gastroenterological Association (AGA) demonstrates the need for improved communication, diagnosis and management of IBS

Entera Health, Inc. today celebrates the role of the AGA in commissioning the “IBS in America” national survey of over 3000 IBS sufferers, both diagnosed and undiagnosed, and 302 physicians who treat IBS patients. The AGA claims it as the most comprehensive IBS survey ever conducted of patients and physicians, examining the complexities around becoming diagnosed with IBS, the physical and emotional impact of the condition, and patient satisfaction with current treatment modalities. Results of the survey were released on...

Read more

Presentation on the benefits of EnteraGam® (serum-derived bovine immunoglobulin/protein isolate, SBI) in patients with pouchitis to occur at the 2015 Advances in Inflammatory Bowel Diseases (AIBD) Annual Meeting

Entera Health, Inc. today announced an upcoming presentation of results from a retrospective chart review of patients with pouchitis who were placed on SBI therapy because they were refractory to other treatment options. Nutritional therapy with SBI helped patients achieve clinical, asymptomatic remission of their pouchitis in 9 out of 10 cases that were reviewed. The presentation will be given by Dr. Larry Good (State University of New York at Stony Brook & South Nassau Communities Hospital, Oceanside, NY) at the 2015 AIBD A...

Read more

Contact Us